Evidence map›Paper›PMID 30533200›Full record

ArticleOncotarget2018

Polymorphisms in KSHV-encoded microRNA sequences affect levels of mature viral microRNA in Kaposi Sarcoma lesions.

Vickie A Marshall, Nazzarena Labo, Joanna Sztuba-Solinska, Elena M Cornejo Castro, Karen Aleman, Kathleen M Wyvill, Lynne McNamara, Stuart F J Le Grice, Robert Yarchoan, Thomas S Uldrick and 3 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 2 countries.

Vickie A MarshallAIDS and Cancer Virus Program, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Nazzarena LaboAIDS and Cancer Virus Program, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Joanna Sztuba-SolinskaBasic Research Laboratory, Center for Cancer Research, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Elena M Cornejo CastroAIDS and Cancer Virus Program, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Karen AlemanHIV and AIDS Malignancy Branch, National Institutes of Health, Bethesda, MD, USA.
Kathleen M WyvillHIV and AIDS Malignancy Branch, National Institutes of Health, Bethesda, MD, USA.
Lynne McNamaraDepartment of Internal Medicine, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa.
Stuart F J Le GriceBasic Research Laboratory, Center for Cancer Research, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Robert YarchoanHIV and AIDS Malignancy Branch, National Institutes of Health, Bethesda, MD, USA.
Thomas S UldrickHIV and AIDS Malignancy Branch, National Institutes of Health, Bethesda, MD, USA.
Patrick MacPhailClinical HIV Research Unit, Department of Medicine, University of the Witwatersrand, Johannesburg, South Africa.
Mark N PolizzottoHIV and AIDS Malignancy Branch, National Institutes of Health, Bethesda, MD, USA.
Denise WhitbyAIDS and Cancer Virus Program, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Frederick National Laboratory for Cancer Research · USOffice of AIDS Research · USLeidos (United States) · USUniversity of the Witwatersrand · ZAAuburn University · USCenter for Cancer Research · USNational Institutes of Health · US

Funding

Structural studies with regulatory RNAsZIABC011824 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI LE GRICE, STUART F. J. · 2018 to 2021
$1.6M
CCR NIH HHS HHSN261200800001CNCI NIH HHS HHSN261200800001E
6 · The paper itself

Abstract

Background: We previously reported Kaposi sarcoma-associated herpesvirus (KSHV) microRNA sequence variants in clinical samples correlated with increased risk of multicentric Castleman's disease (MCD). We then demonstrated that microRNAs with variant sequence have different maturation and mature microRNA expression Methods: KSHV microRNA sequences were determined from 20 KS lesions and 4 control skin biopsies from individuals evaluated for KS. Levels of mature KSHV microRNAs were measured with 21 custom small RNA qRT-PCR assays using RNA RNU6B as endogenous control. Results: The levels of 13 KSHV-encoded microRNAs were elevated in KS lesions compared to control biopsies. MicroRNA 9-5p was strongly down regulated in South African vs. US biopsies. Low levels of K12-9-5p were associated with single nucleotide polymorphisms (SNPs) in miR-K12-9-5p, 4-5p, 5-3p, 7-3p and pri-miR-K12-3. One SNP in pri-miR-K12-3 resulted in down regulation of miR-K12-6-3p, 8-3p, 10-3p, 12-5p and the upregulation of 5-5p, illustrating sequence variants outside pre-microRNAs were also associated with changes in mature microRNA levels. Conclusions: The levels of mature KSHV-encoded microRNAs in KS lesions correlate with sequence variation reflecting changes in secondary and tertiary RNA structure.

Indexed as

Kaposi's sarcomaKSHVmicroRNA

Identifiers

PMID30533200
PMCPMC6254685
OpenAlexW2900156426

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.